The Innopolis Foundation announced on the 3rd that it visited Italian pharmaceutical company Angelini Pharma on the 2nd to hold an open innovation meeting aimed at expanding global commercialization of special zone bio technologies and joint R&D cooperation.
Angelini Pharma is a global specialty pharmaceutical company headquartered in Italy, operating in more than 20 countries including Europe and North America, with a core focus on central nervous system treatments.
The delegation included the Brain Disease Research Group at the Korea Institute of Science and Technology, the Memory and Glia Research Group at the Institute for Basic Science, and brain disease drug development company CureBus. At the meeting attended by Angelini Pharma's CEO, participants discussed R&D strategies in the central nervous system field, technology acquisition directions, and ways to expand cooperation.
A series of major technology transfer deals between special zone companies and Angelini Pharma has recently demonstrated the global competitiveness of R&D Special Zone bio technologies.
CureBus, a research institute-affiliated company in the Hongneung Special Zone, signed a technology transfer agreement worth 500 billion won with Angelini Pharma in 2024 based on its neurodegenerative disease treatment candidate 'CV-01'. The company is currently pursuing joint clinical development through the Innopolis Foundation's 'Global Cluster R&BD Program'.
Sovagen, a deep-tech bio company in Daedeok Special Zone, also established a global partnership with Angelini Pharma by signing a 750 billion won agreement in 2025 through technology transfer of its intractable epilepsy drug candidate 'SVG105'.
"The innovative technologies and research capabilities of special zone bio companies are very impressive," said Sergio Marullo di Condojanni, CEO of Angelini Pharma. "We look forward to continuously expanding opportunities for discovering promising pipelines and joint R&D through cooperation with the Innopolis Foundation."
"This visit is an opportunity to further expand cooperation with Angelini Pharma, which has recognized the competitiveness of special zone bio technologies," said Chung Hee-kwon, Chairman of the Innopolis Foundation. "We will advance the Foundation's global technology commercialization programs and strengthen demand-based technology matching and market entry support to further solidify a commercialization ecosystem that directly connects excellent special zone technologies to global markets."